Core Viewpoint - The stock of药捷安康-B (02617) has experienced a significant decline, dropping nearly 18% to a low of 150.2 HKD, which represents a decrease of over 77% from its intraday high of 679.5 HKD on Tuesday [1] Company Overview -药捷安康 was listed on the Hong Kong Stock Exchange on June 23, with an initial offering price of 13.15 HKD and a total share capital of approximately 397 million shares, resulting in an initial market capitalization of around 5.2 billion HKD [1] - The IPO involved a public offering of 15.281 million shares, with cornerstone investors subscribing to about 9.79 million shares, leaving only approximately 5.49 million shares available for trading in the market [1] Market Dynamics - The limited market float of药捷安康 indicates that there are very few tradable shares available in the secondary market, which can lead to increased volatility [1] - On September 8,药捷安康 was included in several indices, including the Hang Seng Innovative Drug Index and the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which may have contributed to its stock price fluctuations [1] - The initial weight of药捷安康 in these indices was approximately 2.63%, suggesting that related index funds would need to passively allocate at least over 600 million HKD to this stock, potentially triggering significant price movements [1]
港股异动 | 药捷安康-B(02617)尾盘跌近18% 较周二高点已跌超77% 总市值已不足600亿港元